395 related articles for article (PubMed ID: 17287157)
1. Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.
Georges GE; Maris MB; Maloney DG; Sandmaier BM; Sorror ML; Shizuru JA; Lange T; Agura ED; Bruno B; McSweeney PA; Pulsipher MA; Chauncey TR; Mielcarek M; Storer BE; Storb R
Biol Blood Marrow Transplant; 2007 Apr; 13(4):423-32. PubMed ID: 17287157
[TBL] [Abstract][Full Text] [Related]
2. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
3. Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma.
Bruno B; Sorasio R; Patriarca F; Montefusco V; Guidi S; Busca A; Scimé R; Console G; Milone G; Marotta G; Dominietto A; Giaccone L; Rotta M; Falda M; Bacigalupo A; Bosi A; Corradini P; Fanin R; Pollichieni S; Boccadoro M;
Eur J Haematol; 2007 Apr; 78(4):330-7. PubMed ID: 17331132
[TBL] [Abstract][Full Text] [Related]
4. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.
Björkstrand B; Iacobelli S; Hegenbart U; Gruber A; Greinix H; Volin L; Narni F; Musto P; Beksac M; Bosi A; Milone G; Corradini P; Goldschmidt H; de Witte T; Morris C; Niederwieser D; Gahrton G
J Clin Oncol; 2011 Aug; 29(22):3016-22. PubMed ID: 21730266
[TBL] [Abstract][Full Text] [Related]
5. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma.
Burroughs LM; O'Donnell PV; Sandmaier BM; Storer BE; Luznik L; Symons HJ; Jones RJ; Ambinder RF; Maris MB; Blume KG; Niederwieser DW; Bruno B; Maziarz RT; Pulsipher MA; Petersen FB; Storb R; Fuchs EJ; Maloney DG
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1279-87. PubMed ID: 18940683
[TBL] [Abstract][Full Text] [Related]
6. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma.
Maloney DG; Molina AJ; Sahebi F; Stockerl-Goldstein KE; Sandmaier BM; Bensinger W; Storer B; Hegenbart U; Somlo G; Chauncey T; Bruno B; Appelbaum FR; Blume KG; Forman SJ; McSweeney P; Storb R
Blood; 2003 Nov; 102(9):3447-54. PubMed ID: 12855572
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma.
Maris MB; Sandmaier BM; Storer BE; Chauncey T; Stuart MJ; Maziarz RT; Agura E; Langston AA; Pulsipher M; Storb R; Maloney DG
Blood; 2004 Dec; 104(12):3535-42. PubMed ID: 15304387
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation.
Baron F; Storb R; Storer BE; Maris MB; Niederwieser D; Shizuru JA; Chauncey TR; Bruno B; Forman SJ; McSweeney PA; Maziarz RT; Pulsipher MA; Agura ED; Wade J; Sorror M; Maloney DG; Sandmaier BM
J Clin Oncol; 2006 Sep; 24(25):4150-7. PubMed ID: 16896000
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma.
Maffini E; Storer BE; Sandmaier BM; Bruno B; Sahebi F; Shizuru JA; Chauncey TR; Hari P; Lange T; Pulsipher MA; McSweeney PA; Holmberg L; Becker PS; Green DJ; Mielcarek M; Maloney DG; Storb R
Haematologica; 2019 Feb; 104(2):380-391. PubMed ID: 30262560
[TBL] [Abstract][Full Text] [Related]
10. Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant.
Feinstein LC; Sandmaier BM; Maloney DG; Maris MB; Gooley TA; Chauncey TR; Hegenbart U; McSweeney PA; Stuart MJ; Forman SJ; Agura EA; Pulsipher MA; Blume KG; Niederwieser DW; Storb RF
Biol Blood Marrow Transplant; 2003 Apr; 9(4):266-72. PubMed ID: 12720219
[TBL] [Abstract][Full Text] [Related]
11. Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
Vaughn JE; Sorror ML; Storer BE; Chauncey TR; Pulsipher MA; Maziarz RT; Maris MB; Hari P; Laport GG; Franke GN; Agura ED; Langston AA; Rezvani AR; Storb R; Sandmaier BM; Maloney DG
Cancer; 2015 Oct; 121(20):3709-16. PubMed ID: 26207349
[TBL] [Abstract][Full Text] [Related]
12. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
[TBL] [Abstract][Full Text] [Related]
13. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.
Rotta M; Storer BE; Sahebi F; Shizuru JA; Bruno B; Lange T; Agura ED; McSweeney PA; Pulsipher MA; Hari P; Maziarz RT; Chauncey TR; Appelbaum FR; Sorror ML; Bensinger W; Sandmaier BM; Storb RF; Maloney DG
Blood; 2009 Apr; 113(14):3383-91. PubMed ID: 19015394
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma.
Ghosh N; Ye X; Tsai HL; Bolaños-Meade J; Fuchs EJ; Luznik L; Swinnen LJ; Gladstone DE; Ambinder RF; Varadhan R; Shanbhag S; Brodsky RA; Borrello IM; Jones RJ; Matsui W; Huff CA
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1903-1909. PubMed ID: 28711728
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia.
Sorror ML; Maris MB; Sandmaier BM; Storer BE; Stuart MJ; Hegenbart U; Agura E; Chauncey TR; Leis J; Pulsipher M; McSweeney P; Radich JP; Bredeson C; Bruno B; Langston A; Loken MR; Al-Ali H; Blume KG; Storb R; Maloney DG
J Clin Oncol; 2005 Jun; 23(16):3819-29. PubMed ID: 15809448
[TBL] [Abstract][Full Text] [Related]
17. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
18. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens.
Maymani H; Lin P; Saliba RM; Popat U; Bashir Q; Shah N; Patel K; Parmar S; Kebriaei P; Hosing C; Ciurea S; Andersson B; Shpall E; Champlin R; Srour SA; Qazilbash MH
Biol Blood Marrow Transplant; 2019 May; 25(5):1039-1044. PubMed ID: 30639822
[TBL] [Abstract][Full Text] [Related]
20. Non-myeloablative conditioning and allogeneic transplantation for multiple myeloma.
Osman K; Elliott B; Mandeli J; Scigliano E; Malone A; Isola L; Grosskreutz C
Am J Hematol; 2010 Apr; 85(4):249-54. PubMed ID: 20162541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
